Skip to main content

Share story

AI

xAI releases Grok 4.7 through its API and developer platforms

xAI releases Grok 4.7 through its API and developer platforms Image: Primary
xAI introduced Grok 4.7 for coding and knowledge work and made it available through the Grok API, Cursor and Grok Build. The model costs $2 per million input tokens and $6 per million output tokens. Independent testing cited by The Decoder placed Grok 4.7 at 46 on the Artificial Analysis Intelligence Index, compared with 53 for both Claude Fable 5.1 and GPT-6. Its agentic-coding result was weaker: 26% on Terminal-Bench 4.0, versus 60% for GPT-6 Astra and 55% for Claude Fable 5.1. The benchmarks therefore show a price-performance tradeoff rather than category-leading capability.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from the-decoder.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

Security
Security

Gyazo breach exposed metadata for 490 million images

A breach at screenshot-sharing service Gyazo exposed nearly 24 million customer records and an additional 490 million image-metadata records, Infosecurity Magazine reported. Attackers exploited an upload-server vulnerability, gain...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...